Temprian Oncology

Executive Summary

Temprian Oncology is a private, early-stage small molecule company headquartered in San Diego, founded in 2021. The company focuses on addressing the high unmet need in melanoma, which affects over 100,000 patients annually in the US and claims approximately 8,000 lives per year. Despite improvements in treatment, outcomes remain devastating, particularly for young patients with a history of high sun exposure or artificial tanning. Temprian's small molecule approach aims to develop novel therapies that could improve survival and quality of life for these patients. As of early 2026, Temprian is in the preclinical stage with no disclosed pipeline or financing details. The company is likely advancing a lead candidate toward IND-enabling studies. Given its early development phase, Temprian represents a high-risk, high-reward opportunity that will require significant capital and clinical validation. Key near-term milestones will be critical to assess the viability of its platform.

Upcoming Catalysts (preview)

• Q4 2026Lead candidate IND filing30% success
• H1 2027Preclinical proof-of-concept data disclosure at a major oncology conference40% success